These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28834677)

  • 1. Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone.
    Fraccarollo D; Galuppo P; Sieweke JT; Napp LC; Grobbecker P; Bauersachs J
    ESC Heart Fail; 2015 Sep; 2(3):150-158. PubMed ID: 28834677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
    Fraccarollo D; Galuppo P; Schraut S; Kneitz S; van Rooijen N; Ertl G; Bauersachs J
    Hypertension; 2008 Apr; 51(4):905-14. PubMed ID: 18299485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a selective aldosterone receptor antagonist in myocardial infarction.
    Delyani JA; Robinson EL; Rudolph AE
    Am J Physiol Heart Circ Physiol; 2001 Aug; 281(2):H647-54. PubMed ID: 11454568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction.
    Sartório CL; Fraccarollo D; Galuppo P; Leutke M; Ertl G; Stefanon I; Bauersachs J
    Hypertension; 2007 Nov; 50(5):919-25. PubMed ID: 17846350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
    Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
    Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction.
    Lax A; Sanchez-Mas J; Asensio-Lopez MC; Fernandez-Del Palacio MJ; Caballero L; Garrido IP; Pastor-Perez FJ; Januzzi JL; Pascual-Figal DA
    JACC Heart Fail; 2015 Jan; 3(1):50-58. PubMed ID: 25458175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing.
    Fraccarollo D; Thomas S; Scholz CJ; Hilfiker-Kleiner D; Galuppo P; Bauersachs J
    Hypertension; 2019 Jan; 73(1):102-111. PubMed ID: 30543467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.
    Kanashiro-Takeuchi RM; Heidecker B; Lamirault G; Dharamsi JW; Hare JM
    Clin Transl Sci; 2009 Apr; 2(2):134-42. PubMed ID: 20072663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction.
    Enomoto S; Yoshiyama M; Omura T; Matsumoto R; Kusuyama T; Kim S; Izumi Y; Akioka K; Iwao H; Takeuchi K; Yoshikawa J
    Heart; 2005 Dec; 91(12):1595-600. PubMed ID: 15797934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.
    Raman SV; Hor KN; Mazur W; Cardona A; He X; Halnon N; Markham L; Soslow JH; Puchalski MD; Auerbach SR; Truong U; Smart S; McCarthy B; Saeed IM; Statland JM; Kissel JT; Cripe LH
    J Am Heart Assoc; 2019 Oct; 8(19):e013501. PubMed ID: 31549577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
    Weir RA; Tsorlalis IK; Steedman T; Dargie HJ; Fraser R; McMurray JJ; Connell JM
    Eur J Heart Fail; 2011 Dec; 13(12):1305-13. PubMed ID: 21940729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
    Rossignol P; Cleland JG; Bhandari S; Tala S; Gustafsson F; Fay R; Lamiral Z; Dobre D; Pitt B; Zannad F
    Circulation; 2012 Jan; 125(2):271-9. PubMed ID: 22128223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction.
    Masson S; Staszewsky L; Annoni G; Carlo E; Arosio B; Bai A; Calabresi C; Martinoli E; Salio M; Fiordaliso F; Scanziani E; Rudolph AE; Latini R
    J Card Fail; 2004 Oct; 10(5):433-41. PubMed ID: 15470655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction].
    Yoshiyama M; Omura T; Yoshikawa J
    Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):83-9. PubMed ID: 15277726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
    J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR.
    Susic D; Varagic J; Ahn J; Matavelli L; Frohlich ED
    Am J Physiol Heart Circ Physiol; 2007 Jan; 292(1):H175-9. PubMed ID: 16905598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
    Jewell CW; Watson LE; Mock J; Dostal DE
    Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.